Emerging molecular therapies for the treatment of acute lymphoblastic leukemia.

[1]  J. Bueno,et al.  Clofarabine‐based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience , 2012, American journal of hematology.

[2]  F. Bushman,et al.  Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells , 2012, Science Translational Medicine.

[3]  H. Kantarjian,et al.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.

[4]  K. Miyamura,et al.  Allogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia , 2012, Leukemia & lymphoma.

[5]  A. Advani,et al.  Antibody Therapy for Acute Lymphoblastic Leukemia , 2012, Current Hematologic Malignancy Reports.

[6]  M. L. Boer,et al.  The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells , 2012, Leukemia.

[7]  Jingjing Xu,et al.  Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity , 2011, Leukemia & lymphoma.

[8]  H. Einsele,et al.  Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial , 2011 .

[9]  Xiaomin Lu,et al.  Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2 , 2011 .

[10]  I. Pastan,et al.  Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox , 2011, Clinical Cancer Research.

[11]  R. Lutz,et al.  SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies , 2011, Clinical Cancer Research.

[12]  A. Hüttmann,et al.  High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. , 2011, Blood.

[13]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[14]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Porter,et al.  Chimeric Antigen Receptor Therapy for B-cell Malignancies , 2011, Journal of Cancer.

[16]  R. Foà,et al.  Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases , 2011, Leukemia & lymphoma.

[17]  P. Baeuerle,et al.  Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. , 2011, Experimental cell research.

[18]  J. McCubrey,et al.  Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia , 2011, Leukemia.

[19]  H. Kantarjian,et al.  Final Report of a Phase I Trial of Decitabine with or without hyperCVAD In Relapsed Acute Lymphocytic Leukemia (ALL) , 2010 .

[20]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[21]  M. Andreeff,et al.  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Z. Estrov,et al.  Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact , 2010, Epigenetics.

[23]  S. Okabe,et al.  Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells , 2010, Annals of Hematology.

[24]  S. Jagannath,et al.  Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. , 2010, Clinical lymphoma, myeloma & leukemia.

[25]  F. Uckun,et al.  Polo‐like‐kinase 1 (PLK1) as a molecular target to overcome SYK‐mediated resistance of B‐lineage acute lymphoblastic leukaemia cells to oxidative stress , 2010, British journal of haematology.

[26]  A. Angiolillo,et al.  A phase II study of Campath‐1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report , 2009, Pediatric blood & cancer.

[27]  C. Bloomfield,et al.  Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). , 2009 .

[28]  H. Dombret,et al.  Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia . , 2009 .

[29]  Yasuaki Yamada,et al.  Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells , 2009, Leukemia.

[30]  W-S Xu,et al.  Histone deacetylase inhibitors: Potential in cancer therapy , 2009, Journal of cellular biochemistry.

[31]  S. Grant,et al.  MEK Inhibitors Potentiate Dexamethasone Lethality in Acute Lymphoblastic Leukemia Cells through the Pro-apoptotic Molecule BIM , 2009, Leukemia.

[32]  P. Kufer,et al.  Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab , 2009, Leukemia & lymphoma.

[33]  Xiaochun Li,et al.  Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial. , 2008 .

[34]  G. Basso,et al.  CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. , 2008, Blood.

[35]  M. Borowitz,et al.  Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Packham,et al.  Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling* , 2008, Journal of Biological Chemistry.

[37]  P. Kivisäkk,et al.  Jagged1 and Delta1 Differentially Regulate the Outcome of Experimental Autoimmune Encephalomyelitis1 , 2007, The Journal of Immunology.

[38]  C. Bifulco,et al.  A novel regimen incorporating the concomitant administration of fludarabine and alemtuzumab for the treatment of refractory adult acute lymphoblastic leukaemia: a report of three cases , 2007, British journal of haematology.

[39]  Jorge Cortes,et al.  Flying under the radar: the new wave of BCR–ABL inhibitors , 2007, Nature Reviews Drug Discovery.

[40]  S. Plon,et al.  A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study , 2007, Clinical Cancer Research.

[41]  F. Ravandi,et al.  Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report). , 2006 .

[42]  Tomoko Watanabe,et al.  CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. , 2006, Clinical immunology.

[43]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Aster,et al.  A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Scapin,et al.  The crystal structure of the small GTPase Rab11b reveals critical differences relative to the Rab11a isoform. , 2006, Journal of structural biology.

[46]  H. Kantarjian,et al.  Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.

[47]  C. Pui,et al.  Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.

[48]  J. Kurtzberg,et al.  Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[50]  David Allman,et al.  Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. , 2004, Blood.

[51]  E. Estey,et al.  Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias , 2004, Clinical Cancer Research.

[52]  J. Swedlow,et al.  Mitotic mechanics: the auroras come into view. , 2003, Current opinion in cell biology.

[53]  H. Kantarjian,et al.  Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. , 2003, Blood.

[54]  A. Look,et al.  Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. , 1997, Blood.

[55]  J. McCubrey,et al.  AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications , 2012, Leukemia.

[56]  G. Henze,et al.  Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia , 2011, Leukemia.

[57]  Iannis Aifantis,et al.  γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia , 2009, Nature Medicine.

[58]  Penny Levene.  The Spanish experience , 1993 .